IL1F10 and colorectal carcinoma: Although the counteractive role between IL-38 (55) and IL-36s (66) in the development of CRC remains to be confirmed, considering the known anti-inflammatory role of IL-38 and pro-inflammatory role of the IL-36 isoforms, this mechanism likely contributes to the dysregulated intestinal immunity that occurs during CRC pathogenesis.